Mobius Scientific

Executive Summary

Mobius Scientific is a San Diego-based targeted biologics therapeutics company pioneering a novel platform to address progressive vision loss, with an initial focus on age-related macular degeneration (AMD). Unlike current treatments that manage symptoms, Mobius aims to treat the root cause of retinal disease by delivering biologics precisely to diseased cells, potentially halting or reversing vision loss. The company's technology leverages proprietary targeting mechanisms to enhance drug localization and reduce systemic side effects, offering a differentiated approach in the competitive ophthalmology space. Founded in 2015, Mobius remains in early-stage development but has the potential to address a significant unmet need in AMD, which affects millions globally. Its platform could also be extended to other retinal conditions, providing a pipeline-in-a-product opportunity. While the company is private and has not disclosed funding rounds or valuation, its innovative science and focused strategy position it as a compelling candidate for investors seeking exposure to next-generation retinal therapies.

Upcoming Catalysts (preview)

• Q2 2027Initiation of first-in-human Phase 1/2 clinical trial for lead AMD candidate55% success
• Q4 2026Presentation of preclinical efficacy data for platform extension into diabetic retinopathy70% success
• Q3 2026Completion of Series A or B financing round to support clinical development40% success